Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AZ Rides PACIFIC Wave To Be First In Early-Stage NSCLC

Executive Summary

After Imfinzi's failure in the MYSTIC trial, AstraZeneca is very much back in the lung cancer game following the success of the PACIFIC study.


Related Content

The Year's Clinical Trials In Review: Big Hits In 2017
The Year's Clinical Trials In Review: Big Misses In 2017
AstraZeneca's Pipeline Reaps Rewards Of Return To Science
Roche Powers Forward With First-Line Tecentriq In Advanced NSCLC
Wider Than AZ’s PACIFIC – Novartis Has Broad NSCLC Plans For Canakinumab


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts